Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden

AIMS: To assess the cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab added to standard-of-care lipid-lowering treatment [maximum tolerated dose (MTD) of statin and ezetimibe] in Swedish patients with a history of myocardial infarction (MI). METHODS AND R...

Descripción completa

Detalles Bibliográficos
Autores principales: Landmesser, Ulf, Lindgren, Peter, Hagström, Emil, van Hout, Ben, Villa, Guillermo, Pemberton-Ross, Peter, Arellano, Jorge, Svensson, Maria Eriksson, Sibartie, Mahendra, Fonarow, Gregg C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728027/
https://www.ncbi.nlm.nih.gov/pubmed/33063111
http://dx.doi.org/10.1093/ehjqcco/qcaa072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728027/
https://www.ncbi.nlm.nih.gov/pubmed/33063111
http://dx.doi.org/10.1093/ehjqcco/qcaa072

Ejemplares similares